GENEREX AWARDED PATENTS IN NORTH AND SOUTH AMERICA.Generex Biotechnology Corporation (Nasdaq:GNBT), Worcester,Mass., has received new patents in Canada and Argentina. The Canadian Intellectual Property Office The Canadian Intellectual Property Office (CIPO) is the patent, trademark, and copyright administration body of Canada. See also
adj. 1. Of, relating to, adjacent to, or in the direction of the cheek. 2. Of or relating to the mouth cavity. buccal administration. The National Institute of Industrial Property of Argentina has granted the company a new patent titled, "Proteinic Drug Delivery System Using Membrane Mimetics." The patent contains process and formulation claims to a mixed liposome liposome (lī`pəsōm', lĭp`ə–), microscopic, fluid-filled pouch whose walls are made of layers of phospholipids identical to the phospholipids that make up cell membranes. pharmaceutical formulation. "We are pleased to continue to expand our patent portfolio, particularly in Canada, as we move towards the regulatory process for Generex Oral-lyn(tm) once the Phase III pivotal study is completed in global sites," said Rose C. Perri, the company's Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. . Generex currently holds an aggregate of 125 patents worldwide (21 of which are United States Patents) and has an aggregate of 90 patent applications pending in various jurisdictions. About Generex Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity oral cavity n. The part of the mouth behind the teeth and gums that is bounded above by the hard and soft palates and below by the tongue and the mucous membrane connecting it with the inner part of the mandible. (with no deposit in the lungs). The company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the company's proprietary RapidMist(tm) device. The company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause . For more information, visit at http://www.generex.com or the Antigen Express website at http://www.antigenexpress.com. or call 212/732-4300. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion